Clinical trials: Neurofilaments Light Chains
Frontotemporal Dementia (FTD), GRN Related Frontotemporal Dementia
Predict to Prevent PGRN Disease
Progranulin (GRN or PGRN) mutations are among the most common genetic causes of frontotemporal lobar degeneration (FTLD). With the advent of gene-specific therapeutic interventions, an accurate knowledge of the presymptomatic…
- Trial name
- PREVENT-PGRN (NCT06711510)
- Testing
- Clinical, behavioral and cognitive evaluation, blood sampling, brain MRI
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Traumatic Brain Injury (TBI), Chronic Traumatic Encephalopathy (CTE)
The Effects of Fish Oil Supplementation on the Brain Health of Collegiate Football Athletes
Determine if the daily docosahexaenoic acid (DHA)/eicosapentaenoic acid (EPA) supplement will reduce serum levels of biomarkers of sub-concussion injuries over a course of American football season among collegiate football…
- Trial name
- NCT04796207
- Testing
- Fish Oil (DPA+EPA 2:1 ratio) Capsules, High Oleic Safflower Oil Capsules
- Where
- United States
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- University of Arizona
Multiple Sclerosis, Tomography, Optical Coherence
Retinal Atrophy and Neurofilament Light Chain in People With Multiple Sclerosis Taking Ofatumumab
This study aims to assess whether, and the degree to which, ofatumumab modulates or reduces rates of retinal atrophy in people with relapsing-remitting MS (RMS), according to baseline serum neurofilament light chain (sNfL) levels.
- Conditions
- Multiple Sclerosis, Tomography, Optical Coherence, Retinal Degeneration, Visual Acuity
- Trial name
- NCT06167642
- Testing
- Ofatumumab
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- Johns Hopkins University
Parkinson Disease
Evaluation of Functional and Biochemical Effectiveness of a Strength Training Protocol in Parkinson's Disease
Parkinson's Disease (PD) is a complex neurodegenerative disorder characterized by the progressive loss of dopaminergic neurons, which results in a range of motor symptoms such as tremor, rigidity, and bradykinesia, as well as…
- Trial name
- POWER-PD (NCT07095400)
- Testing
- strength training
- Where
- Spain
- Volunteers
- 22 people
- Sponsor
- Universidad Villanueva
Multiple Sclerosis, Relapsing-Remitting
MultiSCRIPT-Cycle 1: Personalized Medicine in Multiple Sclerosis - Pragmatic Platform Trial Embedded Within the SMSC
This is a randomized pragmatic clinical trial fully embedded in the Swiss Multiple Sclerosis Cohort to assess whether sNfL biomarker monitoring improves patient-relevant outcomes and care of patients with relapsing-remitting…
- Trial name
- NCT06095271
- Testing
- serum Neurofilament Filament Light chain (sNfL) monitoring
- Where
- 8 sites in Switzerland
- Volunteers
- 920 people
- Sponsor
- University Hospital, Basel, Switzerland
Parkinson Disease
Lithium for Parkinson's: an Extension Trial
This study will examine the effects of 24 weeks of lithium therapy achieving serum lithium levels of 0.25-0.50mmol/L on MRI and blood-based biomarkers in Parkinson's disease patients who have completed one of our current 24-week…
- Trial name
- NCT06592014
- Testing
- Lithium aspartate
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- State University of New York at Buffalo
Multiple Sclerosis, Clinically Isolated Syndrome of Demyelination
Natalizumab for the Treatment of People With Inflammatory Demyelination Suggestive of Multiple Sclerosis, or Definite Multiple Sclerosis, at First Presentation (AttackMS)
Multiple Sclerosis (MS) is a chronic inflammatory \& degenerative disease of the central nervous system (CNS) Recent data from the MS Base registry demonstrated an average delay of 152 - 215 days between first presentation and…
- Trial name
- AttackMS (NCT05418010)
- Testing
- Tyruko Injectable Product
- Where
- 2 sites in United Kingdom
- Volunteers
- 40 people
- Sponsor
- Queen Mary University of London
Intracerebral Hemorrhage, Hemorrhagic Stroke
Outcome Prediction and Recovery After Spontaneous Intracerebral Haemorrhage
Spontaneous intracerebral haemorrhage (ICH) is a severe form of stroke with high mortality and frequent long-term disability. Current tools to predict how an individual patient will recover are limited.
- Trial name
- CR-4-Health (NCT07882784)
- Where
- 3 sites in Austria, Slovenia
- Volunteers
- 300 people
- Sponsor
- University Medical Centre Maribor
Delirium, Postoperative Cognitive Dysfunction
Biomarkers Associated With Postoperative Cognitive Dysfunction
Loss of cognitive function after major surgery is a significant risk in older people. It can occur acutely in the days after surgery as delirium or in months to years later as a persistent reduction in brain function termed…
- Conditions
- Delirium, Postoperative Cognitive Dysfunction, Cognitive Decline, Cognitive Impairment
- Trial name
- NCT05464355
- Testing
- Intraoperative electroencephalography recording, Neurofilament light chain measurement, Tau protein measurement
- Where
- United Kingdom
- Volunteers
- 45 people
- Sponsor
- University of Oxford
Amyotrophic Lateral Sclerosis, Motor Neuron Disease
Neurofilament Light Chain in Amyotrophic Lateral Sclerosis
This study assesses the performance of serum neurofilament light chain (sNfL) in amyotrophic lateral sclerosis (ALS) in a wide range of disease courses, in terms of ALS progression, disease duration, and tracheostomy invasive…
- Trial name
- NfL-ALS (NCT06201650)
- Testing
- Neurofilament light chain
- Where
- 19 sites in Austria, Germany
- Volunteers
- 3,000 people
- Sponsor
- Charite University, Berlin, Germany
Motor Neuron Disease, Amyotrophic Lateral Sclerosis
Clinical Characteristics, Natural History, Health Care Measures, and Genetic Screening in Patients With ALS
Patients with sporadic ALS (sALS), which refers to those without a family history of ALS, are typically not subjected to genetic investigations as part of their standard care. Therefore, their mutation status is often unknown.
- Trial name
- ID-ALS (NCT05852405)
- Where
- Germany
- Volunteers
- 2,000 people
- Sponsor
- Ambulanzpartner Soziotechnologie APST GmbH
Advanced Multiple Sclerosis, Progressive Multiple Sclerosis
ChariotMS - Cladribine to Halt Deterioration in People With Advanced Multiple Sclerosis
MS is a chronic inflammatory and degenerative disease of the central nervous system (CNS) affecting more than 120,000 people in the UK.and 2.5 million people worldwide.
- Trial name
- ChariotMS (NCT04695080)
- Testing
- Cladribine (MAVENCLAD®)
- Where
- 22 sites in United Kingdom
- Volunteers
- 204 people
- Sponsor
- Queen Mary University of London
Traumatic Brain Injury
The Biomarkers in the Hyperbaric Oxygen Brain Injury Treatment Trial (BioHOBIT)
There are no therapeutic agents that have been shown to improve outcomes from severe traumatic brain injury (TBI). Critical barriers to progress in developing treatments for severe TBI are the lack of: 1) monitoring biomarkers…
- Trial name
- NCT04855396
- Where
- 11 sites in United States, Canada
- Volunteers
- 150 people
- Sponsor
- University of Michigan
Multiple Sclerosis
Serum Neurofilament-light Chain and GFAP Levels in Patients From the OFSEP Cohort at Different Landmarks of Multiple Sclerosis
The investigators hypothesize that serum neurofilament-light chain (NfL) levels can provide information about the level of activity and progression of Multiple Sclerosis at different stages and landmarks of the disease.
- Trial name
- NeurofilMS (NCT03981003)
- Testing
- Blood sample
- Where
- 28 sites in France, Martinique
- Volunteers
- 1,150 people
- Sponsor
- Centre Hospitalier Universitaire de Nīmes
Neurofilament Light Chain, Glial Fibrillary Acidic Protein
Analysis of NfL and GFAP in Different Dietary Patterns
This observational study aims to investigate the impact of different dietary patterns on brain tissue biomarkers in healthy young adults by measuring blood levels of NfL and GFAP.
- Conditions
- Neurofilament Light Chain, Glial Fibrillary Acidic Protein, GFAP, Vegan Diet
- Trial name
- NCT07312994
- Where
- Austria
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Salzburger Landeskliniken
Craniosynostosis, Anesthesia
Influence of General Anesthesia on the Dynamic Changes in Brain Damage Markers During and After Craniosynostosis Operations in Infancy
The issue of anesthetics neurotoxicity is one of the most discussed topics in pediatric anesthesiology, thus it opens the question of the safety of commonly used anesthetics in the pediatric patient.
- Trial name
- TAnBrainDam (NCT05911139)
- Where
- Slovakia
- Volunteers
- 45 people
- Sponsor
- Comenius University
Hand Injuries and Disorders, Wrist Sprain
Perineural vs Intravenous Dexamethasone as an Adjuvant to Brachial Plexus Block in Pediatric Hand Surgery
This clinical trial will evaluate the neurological safety and analgesic effectiveness of dexamethasone administered perineurally or intravenously as an adjuvant to brachial plexus block in children undergoing hand or forearm…
- Trial name
- NCT07474909
- Testing
- iv dexamethasone, pn dexamethasone, 0.9%NaCl
- Where
- Poland
- Volunteers
- 150 people
- Sponsor
- Poznan University of Medical Sciences
Acute Stroke
NF-L Chain Measurement in Acute Ischemic Stroke
1. Using neurofilament light chain as a diagnostic tool and predictor of outcome of acute ischemic stroke 2. Using neurofilament light chain in detecting severity in old ischemic stroke
- Trial name
- NCT06090058
- Testing
- Measurement of neurofilament light chain
- Volunteers
- 150 people
- Sponsor
- Assiut University
Hereditary Amyloidosis, Transthyretin-Related, Asymptomatic Carrier State
Observational Study of Neurofilament Light Chain (NfL) as a Biomarker in Asymptomatic Carriers of the Transthyretin (TTR) Variants and Patients With Hereditary Transthyretin-mediated (hATTR) Amyloidosis With Polyneuropathy
This is a single-center observational study evaluating the potential value of NfL as a biomarker for diagnosis, detection of disease onset, monitoring of disease progression, and treatment response in asymptomatic carriers of TTR…
- Trial name
- NCT06360289
- Testing
- Standard of Care
- Where
- France
- Volunteers
- 346 people, healthy volunteers welcome
- Sponsor
- Alnylam Pharmaceuticals
Schizophrenia, Bipolar Disorder
Neurofilament Light Chains and Cognitive Impairment in Chronic Psychiatric Disease
The validation of biomarkers allowing the discrimination of cognitive and behavioral disorders of psychiatric origin from those of neurodegenerative origin would facilitate diagnosis and improve patient management.
- Conditions
- Schizophrenia, Bipolar Disorder, Alzheimer Disease, FTD
- Trial name
- Nfl_COG (NCT04946916)
- Testing
- blood sample taken
- Where
- 2 sites in France
- Volunteers
- 120 people
- Sponsor
- Hôpital le Vinatier